s-adenosylhomocysteine

SAH (S-Adenosylhomocysteine) 属于氨基酸衍生物，是腺苷和半胱氨酸合成的中间体。SAH 是一种 METTL3-METTL14 异二聚体复合物的抑制剂 (IC50=0.9 µM)。SAH 是多种代谢途径中的调节剂。

3-Deazaadenosine hydrochloride 是 S-腺苷高半胱氨酸水解酶的抑制剂，Ki 值为 3.9 µM。 它具有抗炎、抗增殖和抗 HIV 活性。

3-Deazaadenosine is an inhibitor of S-adenosylhomocysteine hydrolase, with a Ki of 3.9 µM, and it has anti-inflammatory, anti-proliferative and anti-HIV activity.

Adenosine Dialdehyde (Periodate-oxidized adenosine) 是嘌呤核苷类似物，是S-腺苷高半胱氨酸水解酶（SAHH）的有效抑制剂（Ki=3.3nM）。Adenosine Dialdehyde 在体内具有较强的抗肿瘤活性。

Aristeromycin (U 99468) 是一种靶向RNA病毒且具有广谱抗病毒作用的抗生素，是S-腺苷同型半胱氨酸水解酶 (AHCY) 抑制剂。

SAHO is a sulfoxide form of the methyl donor S-(5'-adenosyl)-L-methionine chloride and a substrate for radical SAM enzymes.1It is reductively cleaved to S-adenosylhomocysteine , 5'-deoxyadenosine , and 5'-thioadenosine sulfenic acid by the radical SAM enzymes NosL or NosN. 1.Mandalapu, D., Ji, X., and Zhang, Q.Reductive cleavage of sulfoxide and sulfone by two radical S-adenosyl-L-methionine enzymesBiochemistry58(1)36-39(2019)

3-Deazaneplanocin A (DZNep) 是一种组蛋白甲基转移酶 (EZH2) 和 S-腺苷同型半胱氨酸水解酶 (AHCY) 双重抑制剂，具有抗正痘活性，可在动物模型中能够诱导其靶标的蛋白酶体降解并降低毒性，抑制肝脏、肾脏、腹膜和气道的纤维化。

3-deazaneplanocin A HCl 是组蛋白甲基转移酶 (EZH2) 和 S-腺苷同型半胱氨酸水解酶 (AHCY) 抑制剂。

Aristeromycin diphosphate is an inhibitor of S-adenosylhomocysteine hydrolase (AHCY), inducing miR-26a and regulating oncogenic EZH2 expression, showing high inhibitory activity against AHCY, and causing growth inhibition of prostate cancer.

Adenosylhomocysteinase (SAHH; AHCY) 是一种高度保守的酶。Adenosylhomocysteinase 可逆催化 S-腺苷同型半胱氨酸 (SAH) 生成腺苷和 L-同型半胱氨酸。血清外泌体 Adenosylhomocysteinase 水平可作为 HBV-LC 患者预后的生物标志物。

S-Adenosylhomocysteine (SAH) hydrolase is responsible for the reversible hydrolysis of SAH into adenosine and homocysteine. Inhibition of this enzyme leads to the accumulation of SAH within cells, thereby increasing the SAH to S-adenosylmethionine (SAM) ratio and subsequently inhibiting SAM-dependent methyltransferases. (−)-Neplanocin A, a potent and irreversible inhibitor of SAH hydrolase (Ki= 8.39 nM), exhibits significant antitumor activity against mouse leukemia L1210 cells and holds broad-spectrum antiviral properties. Its efficacy notably surpasses that of the reversible inhibitor 3-deazaneplanocin, especially in combating vesicular stomatitis, evidencing a higher potency with ID50 values of 0.07 μg/ml for Neplanocin A versus 0.3 μg/ml for 3-deazaneplanocin.